These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15695871)

  • 21. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
    J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
    Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children.
    Bernsen RM; van der Wouden JC
    Pediatr Allergy Immunol; 2008 Sep; 19(6):544-51. PubMed ID: 18266826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination and autoimmune diseases: the argument against.
    Rubinstein E
    Isr Med Assoc J; 2004 Jul; 6(7):433-5. PubMed ID: 15274538
    [No Abstract]   [Full Text] [Related]  

  • 28. [A special immunization clinic tailors vaccinations].
    Aronsson B; Blennow M
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1675-9. PubMed ID: 18590010
    [No Abstract]   [Full Text] [Related]  

  • 29. Familial adverse events after measles-mumps-rubella (MMR) vaccination.
    Guala A; Garipoli V; Pastore G; Pagani L
    Vaccine; 2002 Jan; 20(7-8):991. PubMed ID: 11803055
    [No Abstract]   [Full Text] [Related]  

  • 30. No epidemiological evidence for infant vaccinations to cause allergic disease [Vaccine 2004;22:3375-85].
    da Cunha SS
    Vaccine; 2005 Jun; 23(30):3875. PubMed ID: 15917107
    [No Abstract]   [Full Text] [Related]  

  • 31. Egg allergy and MMR vaccination.
    Fox A; Lack G
    Br J Gen Pract; 2003 Oct; 53(495):801-2. PubMed ID: 14601358
    [No Abstract]   [Full Text] [Related]  

  • 32. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants.
    Yerkovich ST; Rowe J; Richmond P; Suriyaarachchi D; Heaton T; Hollams E; Ladyman C; Serralha M; Sadowska A; Loh R; Wesselingh SL; Sly PD; Holt PG
    Vaccine; 2007 Feb; 25(10):1764-70. PubMed ID: 17224218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MMR vaccination: new thought.
    Deshmukh V
    Indian Pediatr; 2006 Jun; 43(6):555-6. PubMed ID: 16820670
    [No Abstract]   [Full Text] [Related]  

  • 34. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
    East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk, its perception and the media: the MMR controversy.
    Hackett AJ
    Community Pract; 2008 Jul; 81(7):22-5. PubMed ID: 18655642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
    Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relative merits of the single and triple MMR vaccines.
    Unstead-Joss L
    J R Soc Promot Health; 2005 Jul; 125(4):155; author reply 155. PubMed ID: 16094921
    [No Abstract]   [Full Text] [Related]  

  • 38. The end of the road for the campaign against MMR.
    Fitzpatrick M
    Br J Gen Pract; 2007 Aug; 57(541):679. PubMed ID: 17688775
    [No Abstract]   [Full Text] [Related]  

  • 39. Criteria for choosing a specific vaccine.
    Freed GL
    Arch Pediatr Adolesc Med; 2004 Apr; 158(4):311. PubMed ID: 15066867
    [No Abstract]   [Full Text] [Related]  

  • 40. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM
    Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.